Value Line - The Most Trusted Name in Investment Research - Stock Quotes

Quote Lookup

Please enter a ticker symbol below and click Submit.
Symbol:        VL Survey Page (2014-10-10)Premium Content

Celgene Corporation (CELG)

2014-10-22@15:14:41 ET
Shares of Celgene Have Risen Above Previous 52-Week High (F71)

2014-10-22@09:10:00 ET
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix (PRN)

2014-10-21@19:18:51 ET
Phase II Data in Crohn's Disease for Celgene's Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014 (ABW)

2014-10-21@14:36:30 ET
Celgene Trading Higher on 1.4x Above-Average Volume (CELG) (F82)

2014-10-21@13:47:36 ET
Celgene (CELG) Breaks Through Resistance at $93.51 (F79)

2014-10-20@16:45:38 ET
Watch for Celgene to Potentially Pullback After Gaining 4.40% Yesterday (PSM)

2014-10-20@16:45:08 ET
Look for Shares of Celgene to Potentially Pullback after Yesterday's 4.40% Rise (PSM)

2014-10-20@13:29:48 ET
Celgene Shares Climbing Higher, Up 3.4% (F77)

2014-10-20@12:13:43 ET
Celgene Crosses Above its 10-day MA (CELG) (F78)

2014-10-20@10:02:52 ET
Next Resistance Level for Celgene (CELG) is $90.67 (PSM)

2014-10-20@07:35:02 ET
Phase II Data in Crohn's Disease for Celgene's Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014 (BIZ)

2014-10-17@11:08:31 ET
Celgene (CELG) Breaks Through Resistance at $87.96 (F79)

2014-10-16@12:18:58 ET
Celgene Makes a Move: Down 1.9% (F77)

2014-10-15@09:10:00 ET
Technical Scrutiny on Health Care Sector Stocks - ImmunoGen, Arrowhead Research, Chimerix, Tekmira Pharma, and Celgene (PRN)